Akston Biosciences

Akston Chooses Louisiana for Major Life Sciences Manufacturing Expansion

Leslie BHA2026-03-02T11:33:12-05:00SHREVEPORT, La. — Akston, a biotechnology company focused on animal health, has opened a new manufacturing facility as part of a $7 million investment in Caddo Parish to expand its U.S. manufacturing capabilities and strengthen Louisiana’s life sciences sector. Read More>>

Akston Initiates Clinical Trial of Once-Weekly GLP-1 Weight-Management Therapy for Cats

Leslie BHA2025-11-26T13:02:28-05:00BEVERLY, Mass., Nov. 25, 2025 /PRNewswire/ -- Akston, the Biotech Built for Pets, announced today the start of a clinical study at Cornell University College of Veterinary Medicine to evaluate its once-weekly GLP-1 weight-management therapy for cats. The trial will assess the therapy over a roughly three-month period in client-owned domestic cats affected by excess weight. Excess weight is one of the most common health issues in cats today. According to the Association for Pet Obesity Prevention (APOP)1, 61% of U.S. cats...

Akston Named Best Start-Up for 2024 in the S&P Global Animal Health Awards

Antonette Ho2025-02-19T03:19:58-05:00Akston, the biotech built for pets, has been awarded the Best Start-Up of 2024 by S&P Global Animal Health at the Animal Health, Nutrition, and Technology Innovation Europe 2025 conference in London. The award was presented by Joseph Harvey, Editor, S&P Global Animal Health, and accepted by Akston CEO, Todd Zion. Read more >>

Purdue University and Akston Biosciences Bring “First Dose of Hope” in New Cancer Immunotherapy Trial for Dogs with Urinary Bladder Cancer

Antonette Ho2025-02-15T23:45:59-05:00Purdue University and its College of Veterinary Medicine, in partnership with Akston Biosciences Corporation, has initiated the enrollment of dogs with urinary bladder cancer in a clinical trial of a pioneering immunotherapy. The immunotherapy consisting of an anti-cPD-L1 monoclonal antibody (mAb) is designed to target and block the cPD-L1 protein on cancer cells. This, in turn, is expected to enhance the immune system's ability to attack the cancer cells more effectively to improve outcomes and extend life. The strategic partnership...

Purdue and Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development

Antonette Ho2024-08-19T02:21:45-04:00Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, and Purdue University, today announced a strategic partnership to co-develop an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy to treat cancer in dogs. In the partnership, Akston has received an exclusive option to license the anti-cPD-L1 mAb and will serve as a Contract Development and Manufacturing Organization (CDMO) to further develop and produce the antibody at its facility in Beverly, Massachusetts.

Dechra Purchases Veterinary Insulin Programs from Akston Biosciences

Antonette Ho2024-08-15T00:08:30-04:00Dechra Limited, a global specialist veterinary pharmaceuticals and related products business, and Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announces Dechra’s purchase of all Akston’s interests in the companies’ dog and cat long-acting insulin programs. Dechra’s purchase gives it ownership of the intellectual property and rights for the development, manufacturing, and worldwide commercialization of both programs. For its interests, Akston receives an upfront cash payment, fees to support technology transfer, and near-term milestone payments...

Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors

Antonette Ho2024-06-30T13:25:56-04:00Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announced the appointment of Linda Rhodes, VMD, PhD to its Board of Directors. Dr. Rhodes brings Akston thirty years of experience in the animal health industry as a scientist, senior executive, and board member. Dr. Rhodes said, “I enjoy working with early-stage companies that have innovative solutions for animal health unmet needs. Akston combines a track record of inventing pioneering new therapies with the in-house capabilities critical...

Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Antonette Ho2024-03-23T17:42:29-04:00Akston Biosciences, dedicated to accelerating the next revolution in Animal Health, announced the publication in Frontiers in Immunology of a study on AKS-107, an innovative antigen-specific immunotherapy based on Akston's Ambifect® Fc-fusion protein platform. The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D). Fc-fusion proteins based on this platform can be designed to interact only with parts of the immune system related to the target disease...

Akston Biosciences’ AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform’s Versatility

Antonette Ho2024-02-27T23:27:09-05:00Akston Biosciences, dedicated to accelerating the next revolution in Animal Health, announced the publication in Nature Vaccines of phase II study results for AKS-452, based on Akston’s Ambifect® Fc-fusion protein platform. This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine. Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures...

Akston Biosciences wins Innovation Award at Animal Health Summit

Antonette Ho2023-09-12T00:00:41-04:00Akston Biosciences Corp, a Massachusetts-based startup focused on developing long-acting protein therapeutics for pets, has received the Innovation Award at the the 2023 Animal Health Summit hosted by KC Animal Health Corridor at the Midland Theatre in Kansas City, Missouri. This is the highest distinction a company can achieve at the event. During the Emerging Companies part of the summit which consisted of a “Shark Tank-style” presentation, Akston Biosciences was among 13 animal health startups to describe their visions for...